• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»Gemelli Biotech

Why Gemelli Biotech’s 3-gas breath test could reshape how clinicians evaluate SIBO

By Pallavi Madhiraju on April 30, 2026   Medical Devices & Diagnostics  

Why Gemelli Biotech’s 3-gas breath test could reshape how clinicians evaluate SIBO

Gut diagnostics need proof, not buzz. Gemelli Biotech’s DDW 2026 visibility could test whether IBS and SIBO care is ready for precision tools.

Recent Posts

  • What Chiesi’s $1.9bn KalVista deal reveals about the next phase of rare disease consolidation
  • Can Chest Wall Innovations turn FDA clearance into adoption in rib fixation?
  • Paradigm Health’s FDA collaboration puts clinical trial data automation under the spotlight
  • Can Earflo reduce ear tube surgery pressure with its FDA-cleared pediatric device?
  • Why Gemelli Biotech’s 3-gas breath test could reshape how clinicians evaluate SIBO
  • What Syncromune Inc.’s SYNC-T data reveals about the future of combination immunotherapy
  • How Imviva Biotech is positioning allogeneic CAR-T therapy for autoimmune disease disruption
  • Tempest Therapeutics, Inc. bets on dual-targeting CAR-T to address antigen escape challenges
  • Is Rein Therapeutics, Inc.’s Phase 2 execution enough to differentiate LTI-03 in IPF
  • Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?
  • Why the FDA breakthrough pathway matters for Laguna Diagnostics’ psychiatric test
  • Why Abbott’s Ultreon 3.0 could reshape stent planning in complex coronary disease
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes